Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Memento Medicines
Memento Medicines

Memento Medicines

Series A

Memento Medicines is a Boston-based biotech developing biologic therapies for retinal diseases.

HQ
Boston, MA, US
Founded
2026
Overview
Analysis
Compare
Fundraising
Employees
News

Memento Medicines, Inc. is a privately held biotechnology company based in Boston, Massachusetts, that develops novel antibody therapies for ophthalmology. Founded in 2026 as the fifth subsidiary of Sera Medicines, a biologics-focused antibody accelerator formed in collaboration with RA Capital, the company is committed to developing new therapies for patients with retinal diseases.

The company's lead program, MMT-205, is a potential best-in-class bispecific antibody that activates Tie2 and inhibits VEGF, in development for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). MMT-205 was licensed from MabTics Co., Ltd. and Curacle Co., Ltd., and proceeds from the company's $93 million Series A financing will support IND-enabling studies, with clinical trials expected to initiate in 2027.

Memento Medicines - Products & Services

  • MMT-205 logo

    MMT-205

    MMT-205 is a Tie2-activating, VEGF-inhibiting bispecific antibody for retinal diseases.

    Competing Products

    Regeneron Ph logo
    Roche Holding logo

Memento Medicines - Similar Companies

Neumedics logo

Neumedics

Triveni Bio logo

Triveni Bio

triveni.bio

Momento Med logo

Momento Med

mementocare.life

Seeing Medicines logo

Seeing Medicines

Faze Medicines logo

Faze Medicines

fazemed.com

MindSet Rx logo

MindSet Rx

Moma Therapeutics logo

Moma Therapeutics

Vision Medicines logo

Vision Medicines

Neovista logo

Neovista

EpiBiologics logo

EpiBiologics

epibiologics.com

Macuclear logo

Macuclear

Adtech Pharma logo

Adtech Pharma

adtechpharma.com

Eumentis Therapeutics logo

Eumentis Therapeutics

Enable Therapeutics logo

Enable Therapeutics

Vitreoretinal Technologies logo

Vitreoretinal Technologies

Memento Medicines - Quick Facts

Who are Memento Medicines' competitors?

Companies similar to Memento Medicines include Neumedics, Triveni Bio, Momento Med and Seeing Medicines.

When was Memento Medicines founded?

Memento Medicines was founded in 2026.

Where is Memento Medicines' headquarters located?

Memento Medicines' headquarters is located in Boston, MA, US.

When was Memento Medicines' last funding round?

Memento Medicines' most recent funding round was for $93M (USD) in June 2026.

How much has Memento Medicines raised to-date?

As of Jun 18, 2026, Memento Medicines has raised a total of $93M (USD).

Memento Medicines - Classification

Industry
  • Biotechnology
Technology
  • Antibody Engineering
Geographic Exposure
  • United States
Model
  • Biotechnology Company
Revenue
  • Pre-Revenue
Customer
  • Healthcare Providers